Xolair was first approved by the U.S. Food and Drug Administration (FDA) in June 2003 [1]. It is indicated for the treatment of moderate to severe persistent asthma in patients aged 12 years and older whose symptoms are inadequately controlled with inhaled corticosteroids [1].
What other conditions is Xolair used for?
In addition to asthma, Xolair is also approved for chronic idiopathic urticaria (hives) and allergic rhinitis (nasal polyps) [1]. For chronic idiopathic urticaria, it is used in adults and adolescents 12 years of age and older whose symptoms are inadequately controlled with H1 antihistamine therapy [2]. For allergic rhinitis with nasal polyps, it is indicated for adults 18 years of age and older whose symptoms are inadequately controlled with intranasal corticosteroids [3].
When does Xolair's patent protection expire?
Patent protection timelines for pharmaceuticals can be complex due to various types of patents and potential extensions. Information regarding specific patent expiry dates for Xolair can be found on specialized patent tracking websites [4].
Who manufactures Xolair?
Xolair is a product developed and manufactured by a collaboration between Novartis and Genentech [1].
What clinical data supports Xolair's approval?
The initial FDA approval for Xolair in asthma was based on clinical trials demonstrating its efficacy in reducing exacerbations and improving lung function in patients with moderate to severe persistent asthma [1]. Subsequent approvals for other indications were supported by clinical studies specific to those conditions [2][3].
What are the common side effects of Xolair?
Common side effects reported in clinical trials for Xolair include injection site reactions, pain, swelling, itching, and rash [1]. Other reported side effects include upper respiratory tract infection and headache [1]. There is a risk of anaphylaxis, which can be severe and life-threatening, and can occur minutes to hours after administration. Patients should be monitored for anaphylaxis, and appropriate medical treatment should be readily available [1].
Can biosimilars be developed for Xolair?
The development of biosimilars for biologic drugs like Xolair depends on patent expiry and regulatory pathways. Once relevant patents expire and data exclusivity periods end, companies can begin the process of developing and seeking approval for biosimilar versions [4].
How does Xolair work?
Xolair (omalizumab) is a monoclonal antibody that works by targeting and neutralizing immunoglobulin E (IgE) [1]. In allergic asthma, IgE plays a role in the inflammatory response. By binding to IgE in the blood, Xolair reduces the amount of free IgE available to trigger allergic reactions in the airways, thereby decreasing inflammation and symptom severity [1].
What is the cost of Xolair?
The cost of Xolair can vary significantly based on insurance coverage, geographic location, and dosage. Patients seeking information on pricing and potential financial assistance programs should consult with their healthcare provider and pharmaceutical manufacturer resources [1].
What are the regulatory hurdles for Xolair?
As a biologic drug, Xolair undergoes rigorous review by regulatory agencies like the FDA. This includes extensive clinical trials to demonstrate safety and efficacy for each approved indication, as well as manufacturing process inspections [1].
What are patient concerns regarding Xolair?
Patient concerns often center on the potential for side effects, particularly the risk of anaphylaxis, and the administration method (subcutaneous injection) [1]. Understanding the benefits versus risks, as well as the cost and accessibility of the medication, are also common considerations for patients [1].
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/105344s70,125369s022,700402s033,700403s029lbl.pdf
2. https://www.gene.com/media/press-releases/display?ContentID=26852
3. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-xolair-omalizumab-allergic-rhinitis-nasal-polyps
4. https://drugpatentwatch.com/